Granted Patent B2

US 12,552,792 · App. 17/931,377 · Granted Feb 17, 2026

Inventors: William Frietze (Kennett Square, PA); Zhongjiang Jia (Kennett Square, PA); Ming Tao (Maple Glen, PA); Jiacheng Zhou (Newark, DE)

Assignee: Incyte Corporation

C07D471/14A61K9/0053A61P35/00C07D471/04C07B2200/13

Abstract

Claims (34)

1 . A solid form of Compound 1 having the formula:

wherein the solid form is crystalline Form I, having characteristic X-Ray Powder Diffraction (“XRPD”) peaks at 6.8±0.2, 9.6±0.2, 12.9±0.2, 18.6±0.2, 19.4±0.2, 22.6±0.2, 25.4±0.2, 25.8±0.2, 26.2±0.2, and 27.5±0.2 degrees 2-theta.

2 . The solid form of claim 1 , wherein the XRPD is measured using X-ray radiation from copper.

3 . The solid form of claim 1 , having at least one endothermic peak at a temperature of 276° C.±3° C. in a differential scanning calorimetry (“DSC”) thermogram.

4 . The solid form of claim 3 , further having an endothermic peak at a temperature of 201° C.±3° C. in a DSC thermogram.

5 . The solid form of claim 1 , wherein Form I is isolated with a crystalline purity greater than about 99%.

6 . The solid form of claim 1 , wherein Form I is isolated with a crystalline purity greater than about 98%.

7 . The solid form of claim 1 , wherein Form I is isolated with a crystalline purity greater than about 97%.

8 . The solid form of claim 1 , wherein Form I is isolated with a crystalline purity greater than about 95%.

9 . The solid form of claim 1 , wherein Form I is isolated with a crystalline purity greater than about 90%.

10 . A pharmaceutical composition comprising a solid form of claim 1 , and a pharmaceutically acceptable excipient.

11 . A solid form of Compound 1 having the formula:

wherein the solid form is crystalline Form I, having characteristic XRPD peaks at 12.9±0.2, 25.4±0.2, and 27.5±0.2 degrees 2-theta; and wherein Form I has endothermic peaks at temperatures of 201° C.±3° C. and 276° C.±3° C. in a DSC thermogram.

12 . The solid form of claim 11 , further comprising characteristic XRPD peaks at 6.8±0.2, 25.8±0.2, and 26.2±0.2 degrees 2-theta.

13 . The solid form of claim 11 , wherein the XRPD is measured using X-ray radiation from copper.

14 . The solid form of claim 11 , wherein Form I is isolated with a crystalline purity greater than about 99%.

15 . The solid form of claim 11 , wherein Form I is isolated with a crystalline purity greater than about 98%.

16 . The solid form of claim 11 , wherein Form I is isolated with a crystalline purity greater than about 97%.

17 . The solid form of claim 11 , wherein Form I is isolated with a crystalline purity greater than about 95%.

18 . The solid form of claim 11 , wherein Form I is isolated with a crystalline purity greater than about 90%.

19 . A pharmaceutical composition comprising a solid form of claim 11 , and a pharmaceutically acceptable excipient.

20 . A solid form of Compound 1 having the formula:

wherein the solid form is crystalline Form I, having an XRPD pattern with characteristic peaks as substantially shown in FIG. 1 .

21 . The solid form of claim 20 , wherein the XRPD is measured using X-ray radiation from copper.

22 . The solid form of claim 20 , having at least one endothermic peak at a temperature of 276° C.±3° C. in a DSC thermogram.

23 . The solid form of claim 22 , further having an endothermic peak at a temperature of 201° C.±3° C. in a DSC thermogram.

24 . The solid form of claim 1 or 20 , having a DSC thermogram substantially as depicted in FIG. 2 .

25 . The solid form of claim 1, 11, or 20 , having a TGA thermogram substantially as depicted in FIG. 3 .

26 . The solid form of claim 20 , wherein Form I is isolated with a crystalline purity greater than about 99%.

27 . The solid form of claim 20 , wherein Form I is isolated with a crystalline purity greater than about 98%.

28 . The solid form of claim 20 , wherein Form I is isolated with a crystalline purity greater than about 97%.

29 . The solid form of claim 20 , wherein Form I is isolated with a crystalline purity greater than about 95%.

30 . The solid form of claim 20 , wherein Form I is isolated with a crystalline purity greater than about 90%.

31 . A pharmaceutical composition comprising a solid form of claim 20 , and a pharmaceutically acceptable excipient.

Assignments (3)

Continuity (4)

References Cited (400)